13F reference period
Q3 2026
CUSIP: 10567X101
13F reference period
Q3 2026
Institutions Reporting
52
Shares (Excl. Options)
Price
$20.20
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 52 institutions filings for Q3 2026.
Security key
10567X101
13F reference period
Q3 2026
13F holders
52
13D/G owners
7
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 10567X101:
13D/G owners
Large-stake holder rows connected to Schedule 13D/G evidence.
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14% | -22% | $335,182,127 | 12,175,159 | 0% | ORBIMED ADVISORS LLC | 08 Sep 2026 | |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 13% | $237,001,517 | 11,640,546 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 30 Sep 2026 | |||
| AH Bio Fund IV, L.P. | 11% | 10,232,420 | AH Bio Fund IV, L.P. | 07 Aug 2026 | ||||
| Murdoch Travis | 9.3% | $177,560,969 | 8,379,470 | Travis Murdoch | 30 Sep 2026 | |||
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 8.2% | $151,073,053 | 7,420,091 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 30 Sep 2026 | |||
| FMR LLC | 8.2% | $150,142,071 | 7,374,365 | FMR LLC | 30 Sep 2026 | |||
| Frazier Life Sciences Public Fund, L.P. | 5.5% | 4,976,457 | Frazier Life Sciences Public Fund, L.P. | 07 Aug 2026 |
13F concentration
Largest 13F positions for this security by reported shares and value.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FCPM III SERVICES B.V. | 24% | 21,826,024 | 42% | $440,885,685 | |
| ORBIMED ADVISORS LLC | 14% | 12,175,159 | 4.5% | $245,938,212 | |
| a16z Capital Management, L.L.C. | 11% | 10,232,420 | 1% | $206,694,884 | |
| Frazier Life Sciences Management, L.P. | 5.8% | 5,267,321 | 2.6% | $106,399,884 | |
| ENAVATE SCIENCES GP, LLC | 4.1% | 3,674,656 | 27% | $74,228,051 | |
| Capital International Investors | 1.4% | 1,300,000 | 0.01% | $26,260,000 | |
| Avoro Capital Advisors LLC | 1.4% | 1,255,000 | 0.26% | $25,351,000 | |
| Capital Research Global Investors | 1.1% | 1,034,097 | 0% | $20,888,759 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.1% | 992,741 | 0% | $20,053,368 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 1% | 910,000 | 0.26% | $18,382,000 | |
| RA CAPITAL MANAGEMENT, L.P. | 0.63% | 565,000 | 0.11% | $11,413,000 | |
| Woodline Partners LP | 0.56% | 502,718 | 0.03% | $10,154,904 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0.52% | 465,251 | 0% | $9,398,070 | |
| EcoR1 Capital, LLC | 0.46% | 416,700 | 0.41% | $8,417,340 | |
| Nextech Invest Ltd. | 0.46% | 416,700 | 0.38% | $8,417,340 | |
| Casdin Capital, LLC | 0.44% | 400,000 | 0.35% | $8,080,000 | |
| Pivotal bioVenture Partners Investment Advisor LLC | 0.35% | 317,351 | 2.5% | $6,410,490 | |
| T. Rowe Price Investment Management, Inc. | 0.34% | 310,097 | 0% | $6,264,000 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.32% | 288,798 | 0% | $5,836,933 | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 0.31% | 277,778 | 0.03% | $5,611,116 | |
| VANGUARD FIDUCIARY TRUST CO | 0.15% | 139,247 | 0% | $2,812,789 | |
| SECTORAL ASSET MANAGEMENT INC | 0.13% | 119,743 | 1.5% | $2,418,809 | |
| PERCEPTIVE ADVISORS LLC | 0.13% | 115,000 | 0.04% | $2,323,000 | |
| SEVEN GRAND MANAGERS, LLC | 0.12% | 112,500 | 0.09% | $2,272,500 | |
| BANK OF AMERICA CORP /DE/ | 0.12% | 108,616 | 0% | $2,194,043 |
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 64,246,939 | $1,297,791,419 | +$1,297,387,419 | $20.20 | 52 |